Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke

Inclusion Criteria: Subjects are eligible for the study if all of the following criteria are met: * Subject is ≥ 18 years old * Has had a recent (within the past 9 days), acute, cortical, hemispheric, ischemic stroke in the MCA distribution without a midline shift as detected by MRI as a diffusion-weighted image (DWI) abnormality * Has a persistent neurological deficit (NIHSS ≥ 7) at the time of enrollment with no more than a 4-point increase (worsening of score) from the screening baseline score compared to NIHSS baseline score at 24 hours prior to infusion. * A platelet count \> 100,000/µL, hemoglobin \> 8 g/dL, and white blood cell count (WBC) \> 2500/µL * Subjects who received tPA or underwent mechanical reperfusion may be included in the study * Is able to provide consent to study or consent is obtained from the subject's legally authorized representative * Subjects of childbearing potential must practice effective contraception during the study, and be willing to continue contraception for at least 6 months after intervention so that, in the opinion of the investigator, they will not become pregnant during the course of the study * Is a good candidate for the study, in the opinion of the investigator * Agrees to participate in follow-up visits Exclusion Criteria: Subjects are excluded from the study if any of the following criteria are met: Medical Conditions * Has a medical history of neurological or orthopedic pathology with a deficit as a consequence that results in an mRS \> 1 before stroke or has a pre-existing cognitive deficit * Has clinically significant and/or symptomatic hemorrhage associated with stroke * Has new intracranial hemorrhage, edema, or mass effect that may place the subject at increased risk for secondary deterioration when assessed prior to infusion * Has hypotension as defined as the need for intravenous pressor support of systolic blood pressure \< 90 mm Hg * Has isolated brain stem stroke * Has pure lacunar stroke * Requires mechanical ventilation * Requires a craniotomy * Has a serious psychiatric or neurological disease that could alter evaluation on functional or cognitive scales * Has an active systemic infection or is human immunodeficiency virus (HIV) positive or hepatitis C positive * Has had an active malignancy within 3 years prior to the start of screening excluding skin cancers other than melanoma * Has known coagulopathy such as Factor V Leyden, antiphospholipid syndrome (APS), Protein C, Protein S deficiency, sickle cell, anticardiolipin antibody, or phospholipid syndrome * Has any concurrent illness or condition that in the opinion of the investigator might interfere with treatment or evaluation of safety * Has a life expectancy \< 6 months * Has current or recent history of alcohol or drug abuse, or stroke associated with drug abuse * Pregnant as documented by urine or blood test * Renal insufficiency with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 * Hepatic insufficiency (bilirubin \> 2.5 mg/dL or transaminases \> 3 × the upper limit of normal). Subjects with Gilbert's syndrome are eligible for study enrollment if other liver function tests are normal, regardless of bilirubin level * Uncontrolled or poorly controlled type 1 or type 2 diabetes with HbA1c \> 7% * Has a history of impaired hemostasis or has a prothrombin time \> 14 seconds/international normalized ratio (INR) \> 1.3 second and activated partial thromboplastin time (aPTT) of \> 70 seconds. * Has a severe persistent neurological deficit (NIHSS \> 24) at the time of enrollment or 24 hours prior to infusion. * Has New York Heart Association Class III or IV congestive heart failure. Concomitant or Prior Therapies * Subjects currently receiving immunosuppressant drugs * Clinical signs and symptoms of infection requiring antibiotic therapy at the time of enrollment that prevent adequate completion of study-related assessments as judged by the investigator * Current therapy with anabolic steroids or appetite stimulants * History of prior transfusion reaction * History of intolerance or allergic response to similar biological products * Known sensitivity to dimethyl sulfoxide (DMSO), Dextran 40, or plasma proteins * Currently on dialysis * Recipient of bone marrow or organ transplant * Any previous or current treatment with angiogenic growth factors, cytokines, gene or stem cell therapy * Subjects participating in another interventional clinical study of an investigational therapy within 30 days of screening Other * Lactating women * Unable to be evaluated for follow-up visits